Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.405
+$0.035 · +2.55%
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Regular session
$1.405
+$0.035 · +2.55%
Regular session · ET · Market data may be delayed.
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Day range
Current $1.405
52-week range
Current $1.405
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
44
Mixed
Risk
73
High Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Day range
Current $1.405
52-week range
Current $1.405
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 4.49M USD | −10.7M USD | 88.03M USD |
| Cost of goods sold | — | — | — | — | 46.43M USD |
| Gross profit | — | — | 4.49M USD | −10.7M USD | 41.59M USD |
| Research and development | 8.99M USD | 158.9M USD | 114.36M USD | 155.51M USD | 190.29M USD |
| Selling, general, and administrative | 4.48M USD | 216.46M USD | 63.91M USD | 199.88M USD | 899.94M USD |
| Operating expenses | 13.48M USD | 375.36M USD | 515.65M USD | 355.38M USD | 2.11B USD |
| Interest income | 1.09M USD | 54.64M USD | 7.3M USD | 4.95M USD | 21.33M USD |
| Interest expense | — | — | 101.85K USD | — | — |
| Depreciation and amortization | 856K USD | 7.11M USD | 7.68M USD | 9.48M USD | 31.63M USD |
| Operating income | −13.48M USD | −375.36M USD | −511.16M USD | −366.08M USD | −2.07B USD |
| Net income | −6.61M USD | −162.26M USD | −1.47B USD | −967.52M USD | −2.33B USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$8.25
487.19% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB889.06K0.01%10.41B USD0.44%$206.28+2.89%
State Street SPDR Portfolio Emerging Markets ETFSPEM413.28K0.00%17.75B USD0.07%$52.145+1.19%
ALPS Medical Breakthroughs ETFSBIO197.06K0.11%187.46M USD0.50%$55.20+2.33%
State Street SPDR S&P China ETFGXC20.66K0.00%452.43M USD0.59%$86.47+1.87%
ProShares Ultra Nasdaq BiotechnologyBIB5.42K0.01%88.27M USD1.19%$111.15+5.84%iShares Biotechnology ETFIBBState Street SPDR Portfolio Emerging Markets ETFSPEMALPS Medical Breakthroughs ETFSBIOState Street SPDR S&P China ETFGXCProShares Ultra Nasdaq BiotechnologyBIBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
